- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 63
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- SOK583A1
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Drug
- Lead sponsor
- Rophibio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
- Conditions
- Retinal Vasculitis
- Interventions
- aflibercept 2 mg
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
- Conditions
- Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- KHK4951, Aflibercept Injection
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 38
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more
- Conditions
- Diabetic Macular Edema
- Interventions
- LKA651, Lucentis
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- aflibercept 8 mg PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • The Woodlands, Texas
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Diego, California + 10 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
- Interventions
- Ixo-vec
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 54
- States / cities
- Mesa, Arizona • Sun City, Arizona • Campbell, California + 50 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Drug
- Lead sponsor
- AsclepiX Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Springfield, Massachusetts • St Louis, Missouri • Asheville, North Carolina + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- SKG0106
- Genetic
- Lead sponsor
- Skyline Therapeutics (US) Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- St. Petersburg, Florida • Boston, Massachusetts • Katy, Texas + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- PDS Implant With Ranibizumab 100 mg/ml, LUCENTIS (Ranibizumab Injection)
- Device · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 52
- States / cities
- Mesa, Arizona • Bakersfield, California • Huntington Beach, California + 47 more
- Conditions
- Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
- Interventions
- observational study, VOY-101
- Other · Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- OTX-TKI
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Santa Barbara, California • Waterford, Connecticut + 4 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 2.0 aflibercept, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 998 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more